Amir Weiss
Known title: Chief Accounting OfficerCIK: 0001897057
Associated companies
this person other insiders at TEVA
Transaction History
| TEVA | ▼ Sell | Open Market | 6,945 | $261K | 8/21/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 2,500 | $49K | 8/21/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 2,500 | $94K | 8/21/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 10,679 | $384K | 5/6/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 3,537 | — | 3/5/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 10,679 | — | 3/4/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 5,650 | — | 3/4/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 5,179 | — | 3/3/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 12,300 | $372K | 12/16/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 12,300 | $301K | 11/6/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 3,566 | — | 3/5/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 10,676 | — | 3/4/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 5,650 | — | 3/4/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 5,179 | — | 3/3/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 12,635 | $210K | 5/16/2024 | View on chart |
| TEVA | ▼ Sell | Open Market | 15,500 | $260K | 5/15/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 3,564 | — | 3/5/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 10,676 | — | 3/4/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 5,179 | — | 3/3/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 3,219 | — | 2/28/2024 | View on chart |
| TEVA | ▼ Sell | Open Market | 31,766 | $393K | 2/1/2024 | View on chart |
| TEVA | ▼ Sell | Open Market | 1,981 | $20K | 8/4/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 3,564 | — | 3/5/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 2,406 | — | 3/4/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 10,676 | — | 3/4/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 3,219 | — | 2/28/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 3,564 | — | 3/5/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 2,403 | — | 3/4/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 981 | — | 3/2/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 3,219 | — | 2/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day
Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.